AR054277A1 - Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst. - Google Patents

Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst.

Info

Publication number
AR054277A1
AR054277A1 AR20060102259A ARP060102259A AR054277A1 AR 054277 A1 AR054277 A1 AR 054277A1 AR 20060102259 A AR20060102259 A AR 20060102259A AR P060102259 A ARP060102259 A AR P060102259A AR 054277 A1 AR054277 A1 AR 054277A1
Authority
AR
Argentina
Prior art keywords
alkoxy
alkyl
formula
halogen
compound
Prior art date
Application number
AR20060102259A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR054277A1 publication Critical patent/AR054277A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Composiciones farmacéuticas que contienen tales compuestos, a un proceso para su obtencion y a la utilizacion de los mismos para tratar y/o prevenir enfermedades asociadas con la modulacion de los receptores del subtipo 5 de la SST. Reivindicacion 1: Compuestos de la formula (1) en la que R1 se elige entre el grupo formado por etilo, 2-fluoretilo, isopropilo e isobutio; R2 se elige entre el grupo formado por hidrogeno, alquilo C1-7, hidroxi, alcoxi C1-7 , cicloalquilo C3-7, -O-cicloalquilo C3- 7, halogeno, halogeno-alquilo C1-7; -C(O)OR6, en el que R6 es alquilo C1-7; -NH-C(O)-R7, en el que R7 es alquilo C1-7; amino, fenilo, fenilo sustituido de una a tres veces por sustituyentes elegidos entre el grupo formado por halogeno, halogeno- alquilo C1-7 y halogeno-alcoxi C1-7; piridilo, imidazolilo, triazolilo y pirrolilo; R3 se elige entre el grupo formado por hidrogeno, alcoxi C1-7, amino, -NH-C(O)-R8 en el que R8 es alquilo C1-7, -O-bencilo y -O-tetrahidropiranilo; o R2 y R3 junto con los átomos de carbono a los que están unidos forman un anillo y R2 y R3 juntos son -CH=CH-NH-; R4 se elige entre el grupo formado por hidrogeno, halogeno, piridilo y pirimidilo; R5 y R5' con independencia entre si se eligen entre hidrogeno o metilo; A se elige entre el grupo formado por fenilo; fenilo sustituido de una a tres veces por sustituyentes elegidos entre el grupo formado por alquilo C1-7, cicloalquilo C3-7, alquilsulfonilo C1-7, -O-alquilsulfonilo C1-7, alquilsulfonil C1-7- alcoxi C2-7, hidroxi, alcoxi C1-7, -O-cicloalquilo C3-7, cicloalquil C3-7-alcoxi C1-7, hidroxi-alquilo C1-7, hidroxi-alcoxi C2-7, dihidroxi-alcoxi C3-7, alcoxi C1-7-alcoxi C2-7, alcoxi C1-7-hidroxi-alcoxi C3-7, alquilamino C1-7, di(alquil C1- 7)amino, amino-alcoxi C2-7, amino-alquilo C1-7, -C(O)NR10R11, -alquileno C1-7-C(O)NR10R11, -O-alquileno C1-7-C(O)NR10R11, -C(O)OR10, -alquileno C1-7-C(O)OR10, -O-alquileno C1-7-C(O)OR10, halogeno, ciano, halogeno-alquilo C1-7, halogeno-alcoxi C1-7, ciano-alcoxi C1-7; fluorofenilo, piridilo, tetrazolilo y tetrazolil-alcoxi C1-7; 1,3-benzodioxolilo; naftilo; pirimidinilo; piridilo; piridilo sustituido por uno o dos sustituyentes elegidos entre el grupo formado por alquilo C1-7, alcoxi C1-7, amino, alquilamino C1-7, di(alquil C1-7)amino, cicloalquilamino C3-7, halogeno, ciano, morfolinilo, imidazolilo, y -NH-C(O)-R9, en el que R9 es alquilo C1-7 o cicloalquilo C3-7, e indolilo; R10 y R11 con independencia entre si son hidrogeno o alquilo C1-7; y las sales farmacéuticamente aceptables de los mismos. Reivindicacion 23: Un proceso para la obtencion de los compuestos segun una cualquiera de las reivindicaciones de 1 a 22, dicho proceso consiste en: a) hacer reaccionar un compuesto de la formula general (2) en la que A tiene el significado definido en la reivindicacion 1, con un aldehído de la formula (3) en la que R1, R2, R3 y R4 tienen los significados definidos en la reivindicacion 1, empleando un agente reductor para obtener un compuesto de la formula (1) en la que R5 y R5' son hidrogeno, y, si se desea, convertir el compuesto de la formula (1) en una sal farmacéuticamente aceptable, o, como alternativa, b) hacer reaccionar un compuesto de la formula (2) en la que A tiene el significado definido en la reivindicacion 1, con un haluro de alquilo de la formula (4) en la que de R1 a R5 y R5' tienen los significados definidos en la reivindicacion 1 y Hal es halogeno, mediante la adicion de una base idonea para obtener un compuesto de la formula (1) y, si se desea, convertir el compuesto de la formula (1) en una sal farmacéuticamente aceptable, o, como alternativa, c) acoplar una amina de la formula general (5) en la que de R1 a R5 y R5' tienen los significados definidos en la reivindicacion 1, con un ácido carboxílico de la formula HOOC-A, en la que A tiene el significado definido en la reivindicacion 1, empleando un agente de acoplamiento apropiado para obtener un compuesto de la formula (1) y, si se desea, convertir el compuesto de la formula (1) en una sal farmacéuticamente aceptable, o, como alternativa, d) acoplar una amina de la formula general (6) en la que de R1 a R5 y R5' tienen los significados definidos en la reivindicacion 1, con un cloruro de ácido de la formula A-C(:O)Cl, en la que A tiene el significado definido en la reivindicacion 1, mediante la adicion de una base idonea para obtener un compuesto de la formula (1) y, si se desea, convertir el compuesto de la formula (1) en una sal farmacéuticamente aceptable.
AR20060102259A 2005-06-02 2006-05-31 Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst. AR054277A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05104774 2005-06-02

Publications (1)

Publication Number Publication Date
AR054277A1 true AR054277A1 (es) 2007-06-13

Family

ID=36763959

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060102259A AR054277A1 (es) 2005-06-02 2006-05-31 Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst.

Country Status (22)

Country Link
US (1) US7772253B2 (es)
EP (1) EP1893603B1 (es)
JP (1) JP4949387B2 (es)
KR (1) KR100962732B1 (es)
CN (1) CN101189226A (es)
AR (1) AR054277A1 (es)
AT (1) ATE445612T1 (es)
AU (1) AU2006254256B2 (es)
BR (1) BRPI0611138A2 (es)
CA (1) CA2608819A1 (es)
DE (1) DE602006009804D1 (es)
DK (1) DK1893603T3 (es)
ES (1) ES2330788T3 (es)
IL (1) IL187426A (es)
MX (1) MX2007014928A (es)
NO (1) NO20076060L (es)
PL (1) PL1893603T3 (es)
PT (1) PT1893603E (es)
RU (1) RU2403250C2 (es)
TW (1) TWI315305B (es)
WO (1) WO2006128803A1 (es)
ZA (1) ZA200710169B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US8026365B2 (en) * 2007-05-25 2011-09-27 Hoffman-La Roche Inc. 4,4-disubstituted piperidine derivatives
EP2491026A1 (en) * 2009-10-20 2012-08-29 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
US8999889B2 (en) 2010-02-01 2015-04-07 Basf Se Substituted ketonic isoxazoline compounds and derivatives for combating animal pests
EP2605658B1 (en) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
CA2812154A1 (en) 2010-10-01 2012-04-05 Basf Se Imine substituted 2, 4 - diaryl - pyrroline derivatives as pesticides
AR084486A1 (es) 2010-10-01 2013-05-22 Basf Se Compuestos de imina
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
EP4153589A1 (en) 2020-05-19 2023-03-29 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH598231A5 (es) 1973-07-27 1978-04-28 Hoffmann La Roche
AR216043A1 (es) * 1974-03-21 1979-11-30 Anphar Sa Procedimiento para la preparacion de 1-derivados de benzoilamino-4-piperidina y sus sales fisiologicamente aceptables
GB1574418A (en) * 1976-11-16 1980-09-03 Anphar Sa Piperidine derivatives
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
JPS5592384A (en) * 1978-12-30 1980-07-12 Beecham Group Ltd Compound having pharmacological activity
US5098915A (en) * 1989-09-05 1992-03-24 G. D. Searle & Co. Substituted N-benzylpiperidine amides
SE9702794D0 (sv) 1997-07-24 1997-07-24 Astra Pharma Prod New compounds
DE60021370C5 (de) 1999-05-04 2007-11-08 Schering Corp. Piperazinderivate verwendbar als ccr5 antagonisten
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
CA2530159C (en) 2003-06-17 2010-02-02 Pfizer Inc. N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
WO2005049573A1 (en) 2003-11-05 2005-06-02 F. Hoffmann-La Roche Ag Phenyl derivatives as ppar agonists

Also Published As

Publication number Publication date
CN101189226A (zh) 2008-05-28
KR100962732B1 (ko) 2010-06-09
NO20076060L (no) 2007-12-28
ZA200710169B (en) 2008-12-31
EP1893603A1 (en) 2008-03-05
RU2007148224A (ru) 2009-07-20
PL1893603T3 (pl) 2010-03-31
KR20080008391A (ko) 2008-01-23
US20060276508A1 (en) 2006-12-07
JP2008545730A (ja) 2008-12-18
IL187426A (en) 2011-10-31
AU2006254256B2 (en) 2012-04-12
IL187426A0 (en) 2008-02-09
ES2330788T3 (es) 2009-12-15
TW200716547A (en) 2007-05-01
PT1893603E (pt) 2009-11-24
ATE445612T1 (de) 2009-10-15
JP4949387B2 (ja) 2012-06-06
BRPI0611138A2 (pt) 2010-08-17
RU2403250C2 (ru) 2010-11-10
AU2006254256A1 (en) 2006-12-07
TWI315305B (en) 2009-10-01
DK1893603T3 (da) 2009-11-30
CA2608819A1 (en) 2006-12-07
US7772253B2 (en) 2010-08-10
MX2007014928A (es) 2008-02-15
WO2006128803A1 (en) 2006-12-07
DE602006009804D1 (de) 2009-11-26
EP1893603B1 (en) 2009-10-14

Similar Documents

Publication Publication Date Title
AR054277A1 (es) Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst.
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR108179A2 (es) Compuestos de pirrolo[2,3-d]pirimidina y sus usos para el tratamiento de diversos tipos de cáncer por medio de la modulación de la actividad de la cinasa de proteína tirosina
AR112834A1 (es) Derivados de rapamicina
AR064561A1 (es) Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR098912A1 (es) Inhibidores de syk
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR113299A1 (es) Compuestos de isoindolina
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR062011A1 (es) Derivados de diazol y sus composiciones como inhibidores de itpkb
AR117544A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
CO6351734A2 (es) Compuestos de amida utiles en terapia
ES2409404T3 (es) Compuestos heterocíclicos de fenoximetilo
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
AR088246A1 (es) Derivados de etinilo
AR091490A1 (es) Antagonistas de iap
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR087771A1 (es) Moduladores de la pde10

Legal Events

Date Code Title Description
FA Abandonment or withdrawal